Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly Janes, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial
Peter B. Gilbert, Youyi Fong, Nima S. Hejazi, et al.
Vaccine (2024) Vol. 42, Iss. 9, pp. 2181-2190
Closed Access | Times Cited: 6
Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection
Emilie Goguet, Cara Olsen, William A. Meyer, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Bo Zhang, Youyi Fong, Lauren Dang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections
José Víctor Zambrana, Ian A. Mellis, Abigail Shotwell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
The Application of DNA Viruses to Biotechnology
Adam J. Schieferecke, Norbert Ralph, David V. Schaffer
Viruses (2025) Vol. 17, Iss. 3, pp. 414-414
Open Access
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
Ying Huang, Nima S. Hejazi, Bryan S. Blette, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 2029-2029
Open Access | Times Cited: 11
Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022
Kelsey M. Sumner, Ruchi Yadav, Emma K. Noble, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 1, pp. 45-54
Open Access | Times Cited: 3
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
Craig A. Magaret, Li Li, Allan C. deCamp, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Progress with COVID vaccine development and implementation
Richard W. Titball, David I. Bernstein, Nicolas V. J. Fanget, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
Sue Ann Costa Clemens, Brett Jepson, Qasim Bhorat, et al.
The Lancet Microbe (2024), pp. 100863-100863
Open Access | Times Cited: 3
Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera
Kun Xu, Yaling An, Xueyuan Liu, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial
Nima S. Hejazi, Xiaoying Shen, Lindsay N. Carpp, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 28-39
Open Access | Times Cited: 9
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
Maheshi Ramasamy, Elizabeth J. Kelly, Seth Seegobin, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 11, pp. e863-e874
Open Access | Times Cited: 8
Anti‐Spike IgG antibodies as correlates of protection against SARS‐CoV‐2 infection in the pre‐Omicron and Omicron era
Lisa Seekircher, Manfred Astl, Lena Tschiderer, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 8
Open Access | Times Cited: 1
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
Avi Kenny, Janine van Duijn, One Dintwe, et al.
EBioMedicine (2024) Vol. 108, pp. 105320-105320
Closed Access | Times Cited: 1
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Youyi Fong, Lauren Dang, Bo Zhang, et al.
Clinical Infectious Diseases (2024) Vol. 80, Iss. 1, pp. 223-227
Closed Access | Times Cited: 1
SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients
Afoke Kokogho, Trevor A. Crowell, Muneerah M Aleissa, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 3
Global prevalence of pre-existing antibodies against human adenoviruses, surveyed from 1962-2021
Hui Luo, Qian Zhou, Jinqi Feng, et al.
Intervirology (2024)
Open Access
Improved estimates of COVID-19 correlates of protection, antibody decay and vaccine efficacy waning: a joint modelling approach
Daniel J. Phillips, Maria D. Christodoulou, S Feng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022
Ryan Sandford, Ruchi Yadav, Emma K. Noble, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 7
Open Access
Navigating the Landscape of B Cell Mediated Immunity and Antibody Monitoring in SARS-CoV-2 Vaccine Efficacy: Tools, Strategies and Clinical Trial Insights
Sophie O’Reilly, Joanne Byrne, Eoin R. Feeney, et al.
Vaccines (2024) Vol. 12, Iss. 10, pp. 1089-1089
Open Access
Modelling antibody dynamics in humans after different Ad26.COV2.S vaccination schemes
Anna Dari, Juan José Perez Ruixo, Mathieu Le Gars, et al.
British Journal of Clinical Pharmacology (2024)
Closed Access
Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021
Yi-Chan Lin, David H. Evans, Ninette F Robbins, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 4
Open Access | Times Cited: 1
Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021–June 2022
Kelsey M. Sumner, Ruchi Yadav, Emma K. Noble, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Advancements in HIV Vaccine Development
Lawrence Corey
touchREVIEWS in Infectious Diseases (2023) Vol. 2, Iss. 1, pp. 3-3
Open Access
Page 1 - Next Page

Scroll to top